Entera Bio Ltd. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On July 14, 2026, Entera Bio shareholders approved an amendment to the 2018 Equity Incentive Plan increasing the aggregate authorized shares by 2,500,000 ordinary shares (par value NIS 0.0000769 each). The Board approved this on May 7, 2026. The filing also includes the company's Articles of Association and an amendment reflecting the share increase to Section 4(a) of the Plan, which now provides for annual increases of the lesser of 5% of outstanding shares or a Board-discretionary amount.
Why this rating
Share reserve increase routine for early-stage biotech; 2.5M shares modest relative to company market cap (~$84.6M); no immediate cash impact or business model change.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.